SK

Sabitha Kalluri

Active Director Director DIN 06975630
DIN 06975630 First appointment Sep 2014 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2014
Shareholding value •••• Premium profile

About Sabitha Kalluri

Data last updated:

Sabitha Kalluri is a Director at Celera Pharma Private Limited (since 2014). The company operates in Pharma. Celera Pharma Private Limited reported revenue of ₹22.48 Cr (FY 2025).

DIN 06975630
Primary Designation Director
Industry Pharma
First Appointment 20 Sep 2014
Oldest Company Age 15 yrs
Largest company Celera Pharma Private Limited · ₹22.48 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Celera Pharma Private Limited U24232TG2011PTC072493
Director20 Sep 20142011₹22.48 Cr (FY 2025)Active

Board colleagues of Sabitha Kalluri

NameDINCompanyDesignation
Ravi Mahanthi09694871Celera Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Celera Pharma Private Limited
Premium access

Shareholding and investment profile for Sabitha Kalluri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sabitha Kalluri

Sabitha Kalluri currently holds 1 directorship: Celera Pharma Private Limited (Director, since 20 Sep 2014, revenue ₹22.48 Cr (FY 2025)).

Sabitha Kalluri was first appointed on 20 Sep 2014 as Director at Celera Pharma Private Limited.

The current boards of Sabitha Kalluri's companies include Ravi Mahanthi (Celera Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available